Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry

Abstract

A paradox persists in contemporary heart failure (HF) care, whereby the therapies most clearly proven to save the most lives are also those most frequently interrupted, often for reasons that are more physiological than pathological. Indeed, during HF medical therapy bradycardia, modest increases in creatinine or potassium levels, mild reductions in blood pressure, and concern regarding hypoglycemia are frequently perceived as dangerous adverse effects of drugs therapy, leading to premature dose reductions or discontinuation. However, when interpreted within their pharmacological and physiological context, these findings more often reflect predictable, dose-related drug effects rather than true toxicity. In the absence of predisposing conditions, such changes are typically modest in magnitude and unlikely to progress to clinically relevant pathological alterations. Recognizing these signals as expected manifestations of effective therapy, rather than harmful events, allows clinicians to maintain evidence-based drugs at target or near-target doses and to fully realize the mortality reduction associated with comprehensive guideline-directed medical therapy (GDMT).